Direxion Daily MSCI South Korea Bull 3X Shares ETF (KORU)
KORU: The Victim Of South Korea's Semiconductor Bottleneck
The Direxion Daily MSCI South Korea Bull 3X ETF is a highly leveraged, volatile ETF now dominated by semiconductor exposure, especially Samsung and SK hynix. KORU's 'Strong Buy' quant rating should be ignored; it's well known that the quant system doesn't account for the ETF's structural risks, leverage decay, or extreme concentration. Despite past momentum, KORU's design ensures long-term underperformance versus its index and amplifies the near-term drawdown seen from lagging the U.S. semis.
Is It Time to Cozy up to KORU Again?
There's no shortage of stocks that provide risk-tolerant traders with excitement. Plenty of ETFs accomplish that objective, too.
KORU Medical Systems Selloff Offers An Opportunity
KORU Medical Systems is transforming into a digitally enabled drug delivery platform, leveraging secular tailwinds in at-home subcutaneous infusion therapies. Q2 revenue grew 18.2% to $12.05M with positive net income and gross margin expansion to 65.1%, driven by domestic core strength and international growth. International ramp is slower than forecast, prompting narrowed FY guidance to $47.5M–$48.5M revenue and a raised gross margin outlook to 62%–64%.
KORU: The Korean Paradox: Record Profits, Prices At Their Lows
The Direxion Daily MSCI South Korea Bull 3X ETF (KORU) has fallen 73% from its highs while the KOSPI dropped 38%, even though SK Hynix's operating profit grew 500% in the same period. The KOSPI's forward P/E fell to 4.5x and its earning yield rose to 22%, driven mainly by forced margin call liquidations rather than weaker earnings. FLKR's daily RSI has already shown a V-shaped recovery near the 30 level, signaling renewed demand interest despite KORU's 3x leverage risks.
KORU Medical Systems Q2 Earnings Call Highlights
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
KORU: Why Bearish South Korea Is The Play Into The Fall
I have a sell rating on Direxion Daily MSCI South Korea Bull 3X ETF due to technical weakness and high volatility. KORU is closely tied to EWY, which is dominated by SK Hynix and Samsung, and faces bearish technical patterns and seasonally weak August–October trends. Despite EWY's low P/E and high EPS growth, cyclical risks in semiconductors and negative compounding in leveraged ETFs warrant caution.
Why the KORU 3X South Korea Bull ETF Is Surging as SK Hynix Rips on HBM4 News
The Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) is Tuesday's standout ETF mover, rising roughly 15% intraday as Korean memory chipmakers stage a sharp rebound behind an SK Hynix HBM4 milestone with NVIDIA.
Memory Demand Is Bullish Sign for This Hot ETF
AI's evolution faces several so-called bottlenecks, including constrained supply for memory semiconductors amid booming demand for those chips. For those who want to focus on domestic names with clear ties to that theme, Micron (MU) usually take the cake.
KORU Is Up 236% Year to Date but Just Lost Half Its Value in a Single Trading Day
If you owned Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) into the close on Friday, June 5, 2026, you watched $10,000 turn into roughly $5,811 in a single session, and you watched a $1,050 share close at $610.
KORU's 274 Percent YTD Gain Looks Stunning Until You See How Fast Daily Resets Can Reverse It
The Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) is up roughly 274% year to date and a stomach-churning 1,500% over the past twelve months, which is a chart that pulls retail money out of money market funds and into a product most of those buyers do not understand.
Magnifying Momentum: Month-to-Date Direxion Inflow Leaders
Today's market uncertainty demands high-conviction trading. With the month of March coming to a close, the latest Direxion leveraged ETF fund flow data reveals a preference for semiconductors, international recovery, and specific high-growth mega-caps.
KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump
KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.
